» Articles » PMID: 30891907

Gestational Diabetes and the Risk of Late Stillbirth: a Case-control Study from England, UK

Overview
Journal BJOG
Date 2019 Mar 21
PMID 30891907
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the separate effects of being 'at risk' of gestational diabetes mellitus (GDM) and screening for GDM, and of raised fasting plasma glucose (FPG) and clinical diagnosis of GDM, on the risk of late stillbirth.

Design: Prospective case-control study.

Setting: Forty-one maternity units in the UK.

Population: Women who had a stillbirth ≥28 weeks of gestation (n = 291) and women with an ongoing pregnancy at the time of interview (n = 733).

Methods: Causal mediation analysis explored the joint effects of (i) 'at risk' of GDM and screening for GDM and (ii) raised FPG (≥5.6 mmol/l) and clinical diagnosis of GDM on the risks of late stillbirth. Adjusted odds ratios (aOR) were estimated by logistic regression adjusted for confounders identified by directed acyclic graphs.

Main Outcome Measures: Screening for GDM and FPG levels RESULTS: Women 'at risk' of GDM, but not screened, experienced 44% greater risk of late stillbirth than those not 'at risk' (aOR 1.44, 95% CI 1.01-2.06). Women 'at risk' of GDM who were screened experienced no such increase (aOR 0.98, 95% CI 0.70-1.36). Women with raised FPG not diagnosed with GDM experienced four-fold greater risk of late stillbirth than women with normal FPG (aOR 4.22, 95% CI 1.04-17.02). Women with raised FPG who were diagnosed with GDM experienced no such increase (aOR 1.10, 95% CI 0.31-3.91).

Conclusions: Optimal screening and diagnosis of GDM mitigate the higher risks of late stillbirth in women 'at risk' of GDM and/or with raised FPG. Failure to diagnose GDM leaves women with raised FPG exposed to avoidable risk of late stillbirth.

Tweetable Abstract: Risk of #stillbirth in gestational diabetes is mitigated by effective screening and diagnosis.

Citing Articles

Circulating miR-486-3p as a potential biomarker for the diagnosis of gestational diabetes mellitus and the prediction of adverse pregnancy outcomes.

Hu Y, Zeng Y, Du X, Li Q, Cao Y, Song H BMC Pregnancy Childbirth. 2025; 25(1):291.

PMID: 40089727 DOI: 10.1186/s12884-025-07405-6.


Enhanced glucose processing in gestational diabetes diagnosis: Effects on health equity and clinical outcomes.

Jones D, Kusinski L, Barker P, Burling K, Halsall I, Turner E Diabet Med. 2024; 42(3):e15476.

PMID: 39687981 PMC: 11823314. DOI: 10.1111/dme.15476.


Early-life menstrual characteristics and gestational diabetes in a large US cohort.

Wang Z, Baird D, Williams M, Jukic A, Wilcox A, Curry C Paediatr Perinat Epidemiol. 2024; 38(8):654-665.

PMID: 39607069 PMC: 11603761. DOI: 10.1111/ppe.13129.


The potential mediating role of the gut microbiome and metabolites in the association between PFAS and kidney function in young adults: A proof-of-concept study.

Hampson H, Li S, Walker D, Wang H, Jia Q, Rock S Sci Total Environ. 2024; 954():176519.

PMID: 39424468 PMC: 11731310. DOI: 10.1016/j.scitotenv.2024.176519.


Maternal Diabetes Mellitus and Neonatal Outcomes in Bisha: A Retrospective Cohort Study.

Alshomrany A, Miskeen E, Alfaifi J, Alshamrani H, Alshahrani A Med Sci (Basel). 2024; 12(2).

PMID: 38651415 PMC: 11036221. DOI: 10.3390/medsci12020021.